They are important additions to Abbott's growing portfolio of molecular diagnostic tests, and represent significant advances in the increasingly important field of genomic testing. The FISH technology platform is uniquely positioned to detect these abnormalities easily and cost effectively in routine clinical laboratories. To extend the use of PathVysion as an aid in the assessment of patients for whom treatment is being considered, Vysis is collaborating with Hoffmann-La Roche Inc. and Genentech, Inc., the developers and marketers of Herceptin , a monoclonal antibody treatment for metastatic breast cancer. The test may provide more accurate identification of patients likely to respond to Herceptin therapy. Determination of HER-2 status has emerged as the standard of care in the assessment of breast cancer cases worldwide.
Bladder cancer is also a leading site of cancer worldwide.
In addition, there are approximately 1.4 million bladder cancer patients in the U.S. and Europe combined that are being routinely monitored for recurrence of the disease. Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals, and medical products, including devices and diagnostics. The company employs approximately 70,000 people and markets its products in more than 130 countries. The statements in this press release concerning Vysis' future results as well as any other statements which are not historical facts, are forward-looking statements and are subject to risks and uncertainties inherent in the company's business. In addition, a detailed discussion of risks and uncertainties may be found in the company's periodic filings with the Securities and Exchange Commission.